Clinical Trial Update: Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET [Phase 1]

View source ↗

Summary

Phase 1 study of TPX-0022 in patients with advanced MET-altered solid tumors, including non-small cell lung cancer and gastric cancer; the trial status is activ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• TPX-0022

Snippet

Sponsor: Turning Point Therapeutics, Inc. | Conditions: Advanced Solid Tumor, Metastatic Solid Tumors | Phase 1 | Status: ACTIVE_NOT_RECRUITING